STOCK TITAN

Ekso Bionics Holdings, Inc. - $EKSO STOCK NEWS

Welcome to our dedicated page for Ekso Bionics Holdings news (Ticker: $EKSO), a resource for investors and traders seeking the latest updates and insights on Ekso Bionics Holdings stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ekso Bionics Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ekso Bionics Holdings's position in the market.

Rhea-AI Summary
Ekso Bionics Holdings, Inc. announces that the Centers for Medicare & Medicaid Services (CMS) has finalized its 2024 Home Health Rule, which includes exoskeletons in the Medicare brace benefit category. This ruling could significantly expand the market for Ekso Indego Personal, a modular and portable exoskeleton that provides increased mobility for individuals with spinal cord injuries. The ruling will go into effect on January 1, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.65%
Tags
none
-
Rhea-AI Summary
Ekso Bionics reports record quarter with $4.6 million in revenue, a 38% YoY increase. Sold 41 EksoHealth devices and achieved record quarter of EVO unit sales. Gross profit of $2.5 million, representing a gross margin of approximately 53%. Net loss narrowed to $3.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.53%
Tags
-
Rhea-AI Summary
Ekso Bionics to release Q3 2023 financial and business results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Summary
Ekso Bionics supports CMS proposal to include personal exoskeletons in Medicare benefit category for braces, potentially expanding market for Ekso Indego Personal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.1%
Tags
none
-
Rhea-AI Summary
Ekso Bionics Holdings to participate in fireside chat at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.38%
Tags
conferences
-
Rhea-AI Summary
Ekso Bionics reports record revenues of $4.7 million in Q2 2023, a 36% YoY increase. They booked a total of 44 EksoHealth devices. Gross profit was $2.3 million with a gross margin of 48%. Cash position is $13.3 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.47%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
none
Ekso Bionics Holdings, Inc.

Nasdaq:EKSO

EKSO Rankings

EKSO Stock Data

24.90M
16.01M
13.5%
7.68%
0.75%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
SAN RAFAEL

About EKSO

since 2005, ekso bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. the company’s first commercially available product called ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. by designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, ekso bionics is helping people rethink current physical limitations and achieve the remarkable. ekso bionics is headquartered in richmond, california international offices: europe/middle east/africa 29th floor one canada square canary wharf london, united kingdom +44 20 7060 3568 kunden service deutschland +49 89 55067774